Multiple sclerosis and diseasemodifying therapies

Neurology

Volumn 77, Issue 4, 2011, Pages

  Minen, Mia T ^a   Karceski, Steven ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; MITOXANTRONE; NATALIZUMAB; RECOMBINANT INTERFERON; IMMUNOSUPPRESSIVE AGENT;

COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; EMERGENCY WARD; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MEDICARE; MULTIPLE SCLEROSIS; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; REIMBURSEMENT; TREATMENT OUTCOME; UNITED STATES; ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; METHODOLOGY;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS;

EID: 80051516356     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318229e6ca     Document Type: Note

References (1)

1. Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology 2011;77:355-363.